Acute monocytic leukemia
MONDO:0007896Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
Also known as: monocytic leukaemia, monocytic leukemia, AML M5, acute monoblastic leukaemia and acute monocytic leukaemia, acute monocytic leukaemia (FAB M5B), acute monocytic leukaemia (FAB M5b), acute monocytic leukemia, acute monocytic leukemia (FAB M5B)
3105 clinical trials for this condition and its sub-types, 20 tagged with Acute monocytic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Acute monocytic leukemia
-
Adult acute monocytic leukemia 4 trials
-
Aleukemic monocytic leukemia cutis 0 trials
-
Subacute monocytic leukemia 0 trials
-
New drug cocktail aims to outsmart resistant leukemia
Disease control OngoingThis phase 2 trial tests a combination of two drugs, cladribine and venetoclax, in 20 adults with a specific form of acute myeloid leukemia (monocytic AML) that has stopped responding to or returned after standard treatment. The goal is to see if this new combo can shrink or elim…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a 'Priming' drug boost chemo for tough leukemia?
Disease control OngoingThis phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New tool aims to improve care for older cancer patients
Knowledge-focused OngoingThis pilot study tests a new assessment tool called IA3-CP for cancer patients aged 65 and older. The tool gathers information on aging-related issues, mental health, health behaviors, and social factors to help doctors provide better, more personalized care. 35 participants are …
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:59 UTC